Publication
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerCholangiocarcinomacivic_curation1.00
- drugInfigratinibcivic_curation1.00
- geneFGFR2civic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
- variantFGFR2 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29182496
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR2 Mutation1 | ||||||||
| Infigratinib | Cholangiocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID5912Eight patients with cholangiocarcinoma haboring FGFR2 mutations received BGJ398. No response was observed, but one tumor showed a 23% reduction in size. Water fall plot of this article showed 5 patie… (full text at CIViC) PMID 29182496 · Javle et al., 2018 · Open in CIViC | civic |
| FGFR2 Fusion + FGFR2 Fusion1 | ||||||||
| Infigratinib | Cholangiocarcinoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID5908This Phase II trial of BGJ398 for FGFR2 aberant cholangiocarcinoma included 48 patients with FGFR2 fusions. Among these patients with FGFR2 fusions, eight showed tumor response (18.8%) and thirty-six … (full text at CIViC) PMID 29182496 · Javle et al., 2018 · Open in CIViC | civic |